Blockade of the immune checkpoint molecule programmed-cell-death-protein-1 (PD-1) yielded promising results in several cancers. To understand the therapeutic potential in human gliomas, quantitative data describing the expression of PD-1 are essential. Moreover, due the immune-specialized region of the brain in which gliomas arise, differences between tumorinfiltrating and circulating lymphocytes should be acknowledged. In this study we have used flow cytometry to quantify PD-1 expression on tumor-infiltrating T cells of 25 freshly resected glioma cell suspensions (10 newly and 5 relapsed glioblastoma, 10 lower grade gliomas) and simultaneously isolated circulating T cells. A strong upregulation of PD-1 expression in the tumor microenvironment compared to the blood circulation was seen in all glioma patients. Additionally, circulating T cells were isolated from 15 age-matched healthy volunteers, but no differences in PD-1 expression were found compared to glioma patients. In the murine GL261 malignant glioma model, there was a similar upregulation of PD-1 on brain-infiltrating lymphocytes. Using a monoclonal PD-1 blocking antibody, we found a marked prolonged survival with 55% of mice reaching long-term survival. Analysis of brain-infiltrating cells 21 days after GL261 tumor implantation showed a shift in infiltrating lymphocyte subgroups with increased CD81 T cells and decreased regulatory T cells. Together, our results suggest an important role of PD-1 in gliomainduced immune escape, and provide translational evidence for the use of PD-1 blocking antibodies in human malignant gliomas.
evidence for previous observations of drainage of antigens from the brain to the cervical lymph nodes. 9 Secondly, ways of influx of leukocytes via several mechanisms into the CNS have been described. 10 Finally, there are intense interactions between brain tumors and the immune system. On the systemic level, both circulating GBM cells 11 and tumor-specific CD81 T cells 12 have been reported. Within the tumor microenvironment it has been shown that the majority of GBM are infiltrated by T cells, amongst other immune cell populations. [13] [14] [15] A positive correlation between the presence of tumor-infiltrating lymphocytes (TILs) and outcome remains controversial, probably because the genetic subtype of the tumor, 14 the presence of suppressive T cell subtypes as regulatory T cells (Tregs) 16 and the activation state of all these T cells have not always been taken into account. The question remains whether TILs are the signature of a cytotoxic anti-tumor response, or rather present an anergic, tolerant immune cell population as part of the immune-suppressive network implemented by malignant gliomas. 17 In the last decade immune checkpoint blockers have caused a revolution in the field of immunotherapy for cancer. Immune checkpoint molecules are a family of surface receptors on T cells that are induced or upregulated after T-cell activation as a negative feedback mechanism. 18 They initiate inhibitory pathways which are essential for maintaining self-tolerance, dampening of (ongoing) inflammatory reactions and preventing autoimmunity. 19 Their importance for the normal function of the immune system was shown in knockout mice that developed uncontrolled immune hyperactivation leading to lethal lymphoproliferative disease. 20 Many cancers exploit these checkpoints to inhibit especially tumor-reactive cytotoxic CD81 T cells. The most studied immune checkpoints in oncology are cytotoxic T-lymphocyte antigen-4 (CTLA-4) and programmed cell death protein-1 (PD-1). 21 For malignant gliomas, PD-1 together with its ligand PD-L1 is believed to be the most promising target based on studies with blocking antibodies in mouse models 22, 23 and the expression of PD-L1 in the human glioma tumor microenvironment. 24, 25 Blocking of the PD-L1/ PD-1 pathway has been shown to re-activate exhausted T cells and restore their cytotoxic function. 26 Inhibition of PD-1 with pembrolizumab or nivolumab has been successfully studied in clinical trials for melanoma, where it was shown to be more effective than CTLA-4 blockade with less severe toxicity. [27] [28] [29] PD-1 blockade also showed to be effective in advanced renal cell carcinoma 30 and non-small-cell lung cancer. 31, 32 Early phase clinical trials evaluating the use of PD-1 blockade in human malignant glioma are underway 33 and a phase III trial of nivolumab for recurrent GBM is currently ongoing (NCT02017717). PD-1 expression on TILs across different glioma grades was documented in only one study by immunohistochemistry, where it was found to increase with higher tumor grade. 34 In our study, we used flow cytometry to evaluate PD-1 expression on tumor-infiltrating T cells of glioma cell suspensions from different glioma grades, and compared this to PD-1 expression on simultaneously isolated circulating T cells. Furthermore, we also evaluated PD-1 expression on circulating T cells in age-matched, healthy volunteers. To assess the mutual validity of translational and preclinical research, we compared the observations in human glioma patients with PD-1 expression in the murine GL261 malignant glioma model. Finally, in the GL261 model, we studied the effects of therapeutic PD-1 blockade using a monoclonal blocking antibody.
Material and Methods

Patients and healthy controls
Blood and tumor tissue were collected from 23 adult patients that underwent neurosurgical resection for a glioma at the University Hospitals Leuven. Two patients were sampled at surgery for newly diagnosed GBM and again at surgery for relapse, making the total number of samples 25. Pathology confirmed newly diagnosed GBM in 10 patients, relapsed GBM in 5 patients, grade 3 anaplastic glioma in 3 patients and grade 2 glioma in 7 patients (Table 1 ). All patients were clinically infection free at the moment of surgery. Blood was also donated by 15 healthy volunteers (no clinical signs of infections; no steroid, antibiotic or cytostatic medication). All patients and healthy volunteers were Caucasian. Age and gender distribution were comparable between the 2 groups ( Table 2 ). All patients and healthy volunteers signed an informed consent before blood and/or tumor samples were taken in the context of the Brain-Tumor-Imm-2014 immune monitoring study. This Brain-Tumor-Imm-2014 study was approved by the local ethical committee.
Mice, cell line and intracranial tumor implantation
Eight to 10 weeks old female inbred C57BL/6 mice were purchased from Envigo (Horst, The Netherlands). Mice were housed under conventional pathogen-free conditions and had free access to food and water. All murine experiments were approved by the Bioethics Committee of kU Leuven. GL261
What's new? Programmed cell death protein-1 (PD-1) and its ligand, PD-L1, are promising therapeutic targets in the fight against glioblastoma, one the most aggressive and lethal forms of brain cancer. Here, flow cytometry was used to quantify PD-1 expression simultaneously on circulating and tumor-infiltrating lymphocytes of glioma patients. Tumor-infiltrating lymphocytes heavily upregulated PD-1 whereas expression on circulating T-cells did not differ from healthy volunteers. Similar upregulation in brain-infiltrating lymphocytes was seen in the murine GL261 glioma model, in which therapeutically blocking PD-1 lengthened survival. The findings justify the further exploration of PD-1 as a target for immunotherapy in the glioma microenvironment.
cells were cultured and used for intracranial tumor induction, as previously described. 35 Briefly, mice were anesthetized and 0.5 3 10 6 GL261 cells were injected in the right hemisphere using a stereotactic frame (Kopf instruments, Tujunga, CA, USA). After intracranial implantation mice were weighed and clinically evaluated 3 times per week. For immune monitoring, randomly selected mice of all treatment groups were sacrificed 21 days after tumor implantation. Fresh brains were used for isolation of brain-infiltrating cells (BIC), or fixed with 4% formaldehyde and embedded in paraffin. Eight sections of paraffin-embedded brains were stained with hematoxylin and eosin (HE) and evaluated for the presence of tumor tissue. All other mice were followed for survival and euthanized at predetermined endpoints: 30% loss of body weight or development of severe neurological symptoms (hunched posture, lethargy, ambulatory failure).
PD-1 blocking antibody and isotype control
The anti-PD-1 hybridoma (Clone RPMI-14) was cultured in Isocove's Modified Dulbecco's Medium (IMDM) (Lonza, Verviers, Belgium) containing 1% FBS. Clarified supernatant was purified Patients numbers 3 and 6 were sampled at surgery for newly diagnosed GBM and again at surgery for a recurrence after completion of standard radiochemotherapy. Time between the first and second surgery in these 2 patients was 290 days (nr. 3) and 365 days (nr. 6).
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using affinity chromatography, dialyzed against PBS and sterilized by 0.2 mm filtration. An isotype control monoclonal antibody (anti-Beta-Galactosidase) was produced identically. In therapeutic experiments, 3 administrations of 200 mg anti-PD-1 or control antibody were given intraperitoneally (ip) 5, 10 and 15 days after intracranial tumor implantation.
Tissue handling and flow cytometry
Immune cell isolation. Peripheral blood mononuclear cells (PBMC) were isolated from fresh blood samples by centrifugation in a density gradient (Lymphoprep TM , Fresenius Kabi, Olso, Norway). For evaluation of tumor-or brain-infiltrating lymphocytes, immune cells were isolated from tissue before staining for flow cytometry. In human experiments, glioma cell suspensions were prepared from at least 1 mm 3 fresh tumor tissue. Visible parts of coagulated tissue and blood vessels were removed. Tumor tissue was then disrupted mechanically with surgical scalpels and chemically by incubation (30 min at 378C) in digestion medium, consisting of preheated culture medium supplemented with 5 U/ml DNAse (Invitrogen, Life Technologies, Carlsbad, CA, USA) and 2.5 mg/ml Collagenase D (Roche, Mannheim, Germany). A single cell suspension was obtained by forcing tumor tissue through a 70 mm Cell Strainer (Greiner, Frickenhausen, Germany). Tumor-infiltrating immune cells were separated from myelin and other cells by centrifugation in a Percoll (Sigma-Aldrich, St-Louis, MO, USA) gradient. In murine experiments, mice were euthanized, perfused, and whole brains were prelevated as previously described. 35 A single cell suspension was prepared from whole brains followed by isolation of immune cells in a Percoll gradient, similar as in the human tumor tissue experiments. Immune cells from spleen and lymph nodes were isolated directly after forcing tissue through a 70 ml cell strainer (Greiner). 
Results
PD-1 expression does not differ between circulating lymphocytes in glioma patients and healthy volunteers
In glioma patients taking corticosteroids at the moment of surgery, a lower percentage of total CD31 T cells within the viable CD451 population was found (Supporting Information Fig. 4  A) . This difference was absent in patients that did not take corticosteroids at the moment of surgery. The relative distribution of CD41 and CD81 T cells within the CD31 T cell gate did not differ (data not shown), but a significantly higher percentage of cells with the Treg phenotype (CD41 CD251 CD127 dim/neg ) was found in the glioma population (mean 9.6% versus 7.2% respectively, p < 0.001) (Supporting Information Fig. 4B ). PD-1 expression did not differ between glioma patients and healthy volunteers: On an average 27.0% of CD81 T cells in patients versus 29.3% in healthy volunteers were positive for PD-1 (p 5 0.61), 17.7% of conventional CD41 T cells in patients versus 19.0% in healthy volunteers (p 5 0.65) and 22.1% of Tregs in patients versus 21.2% in healthy volunteers (p 5 0.72) (Fig. 1a-c) . Also, Median Fluorescence Intensity (MFI) of PD-1 positive cells was not different between patients and healthy volunteers (Supporting Information Fig. 5 A-C) . Within all CD41 T cells, Tregs had a small but significantly higher percentage of PD-1 positive cells (mean 22.1%) than conventional CD41 T cells (mean 17.7%) (p5 0.007) (Supporting Information Fig. 6 A) . In glioma patients, there Age at first surgery was used for the 2 patients that were sampled both at surgery for newly diagnosed GBM and at surgery for recurrent GBM.
were no differences in the proportion of PD-1 positive cells between newly diagnosed GBM, relapsed GBM and lower grade gliomas for all T cell subpopulations ( Fig. 1d-f ).
PD-1 is highly upregulated in the brain tumor microenvironment
Although the total number of T cells that could be isolated from glioma cell suspensions was variable across samples (Supporting Information Fig. 7 ), we were able to identify CD31 T cells and CD41 and CD81 subfractions in all glioma samples. In all samples, a significantly higher percentage of PD-1 positive CD81 and conventional CD41 T cells was seen in Tumorinfiltrating cells (TIC) than in PBMC (Fig. 2a,b) (p < 0.0001). A clear Treg subpopulation in the total CD41 T cell fraction in TIC could not always be sorted out. However, when we analyzed the 15 samples with at least 100 events in the Treg gate, there was also a significantly higher percentage of PD-1 positive Tregs in TIC than in PBMC (Fig. 2c) (p < 0.0001). Moreover, MFI of PD-1 positive cells was significantly higher in TIC than in PBMC for all T cell populations (Supporting Information Fig. 5 D-F) . Contrary to PD-1 on circulating Tregs, we found no difference in relative expression of PD-1 on tumor-infiltrating Tregs versus conventional CD41 T cells (Supporting Information Fig. 6B ). Tumor-infiltrating conventional CD41 T cells of relapsed GBM patients had a trend towards a higher proportion of PD-1 positivity than newly diagnosed GBM or lower grade glioma patients (p 5 0.051). There were no differences between newly diagnosed GBM, relapsed GBM and lower grade glioma for PD-1 positive CD81 T cells and Tregs (Fig. 2d-f ). Interestingly, in 2 patients that were sampled the first time at surgery for newly diagnosed GBM and a second time at relapse, there was an increase in PD-1 positive cells for both CD41 and CD81 T cells in PBMC and TIC at relapse (Supporting Information Fig. 8 ). Both patients relapsed after completing standard radiochemotherapy with 6 cycles of adjuvant temozolomide.
PD-1 expression in the murine GL261 malignant glioma model is low in peripheral tissues but high in the tumor microenvironment
In pilot experiments (9 mice), we found a very low percentage of PD-1 positive cells in cervical and abdominal lymph nodes of tumor-bearing mice: 2% to 4% of CD41 T cells and < 1% of CD81 T cells. In further experiments, we used splenic lymphocytes to measure systemic PD-1 expression. Twenty-one days after GL261 tumor implantation, the mean percentage of PD-1 positive cells in the spleen was 2.4% for CD81 T cells, 4.3% for conventional CD41 T cells and 22.4% for Tregs. This was significantly lower than PD-1 expression BIC, where on average 50.0% of CD81 T cells, 49.1% of conventional CD41 T cells 
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and 54.7% of Tregs were PD-1 positive (all p-values < 0.0001) (Fig. 3a-c) . Similar to human data, Tregs isolated from spleens had significantly higher percentages of PD-1 positive cells than conventional CD41 T cells, but in BIC there was no difference (Supporting Information Fig. 6 C-D) .
Therapeutic blockade of PD-1 induces prolonged survival after GL261 implantation and leads to an increased CD81 and decreased Treg infiltration
After implantation of GL261 tumor cells, mice were randomized between treatment with a PD-1 blocking antibody and an isotype control antibody. We found a significant improved survival after PD-1 blockade. The median survival in the control group was 24.5 days, while this was not reached in the PD-1 blockade group (p < 0.0001). Long-term survival, defined as 3 times the median survival of the control group, was reached in 6 out of 11 (55%) treated mice (Fig. 4) . Four of the long-term surviving mice underwent a second implantation of GL261 cells in the left hemisphere 140 days after the first tumor implantation to check the induction of an immunological memory. After this second tumor implantation these mice were followed clinically and did not receive any treatment. With a follow-up of > 100 days, none of these mice died or showed neurological symptoms.
To evaluate whether PD-1 blockade could influence the immune microenvironment, 10 randomly selected mice per group were sacrificed 21 days after tumor implantation and BIC were isolated for flow cytometry. Both groups had similar CD31 T cell infiltrations, but inside the T-cell fraction mice from the PD-1-blockade group showed a shift towards higher CD81 T cells infiltration (mean 47.0% in PD-1 blockade group versus 33.0% in control group, p 5 0.01) and fewer Tregs (mean 9.5% versus 18.0% respectively, p 5 0.005), while there was no change in conventional CD41 T cells (Fig. 3d-f ). Regarding PD-1 expression after PD-1 blockade, we found the percentage of PD-1 positive Tregs to be significantly lower after PD-1 blockade (mean 40.4% in the PD-1 blockade group versus 54.7% in the control group, p 5 0.0009), while there was only a non-significant decrease in conventional CD41 and CD81 T cells (Fig. 3g-i) . However, MFI of PD-1 positive cells was significantly decreased in all T cell subpopulations after PD-1 blockade (Fig. 4j-l) (p < 0.0001 for CD81 and conventional CD41 T cells, p 5 0.005 for Tregs).
Discussion
To the best of our knowledge, this is the first study that systematically quantifies PD-1 expression on T lymphocytes of human gliomas by flow cytometry. By simultaneously collecting circulating lymphocytes and TILs, we aimed to get insight in the compartmental differences. We have found a strong PD-1 upregulation in the tumor microenvironment, where the majority of T cells were PD-1 positive, while expression on circulating cells was low. This PD-1 upregulation was a highly significant finding in all samples and present on CD81, conventional CD41 and regulatory T cell subfractions. We also showed that this upregulation was not restricted to grade 4 gliomas, but was 
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equally present in grade 2 and grade 3 gliomas. We conclude that PD-1 is highly expressed on all subtypes of tumorinfiltrating T cells in diffuse gliomas. Given the robustness of this finding in our samples, we believe that the relatively small sample size of our study is sufficient to prove this biologically relevant effect. t test (a-c) or an unpaired t test (d-l). * p < 0.05; ** p < 0.01; *** p < 0.0001; ns not significant.
In literature, only a recent study by Garber et al. described PD-1 expression across different glioma grades using immunohistochemistry. 34 They found PD-1 on TILs to be present in 31.5% of gliomas, with a significant correlation with grade 4 lesions and only rare PD-1 positivity in lower grade gliomas. 34 Our data show, however, that PD-1 is expressed on T cells of glioma grades 2, 3 and 4. Flow cytometry has the advantage to be very sensitive to sort out small cell populations in tissue samples. This could explain why we could detect PD-1 positive T cells in all glioma cell suspensions, including lower grade gliomas that have less infiltrating lymphocytes. Moreover, flow cytometry allowed us to identify PD-1 on CD81, conventional CD41 and regulatory T cell subsets whereas the study by Garber evaluated the global T lymphocyte population. The disadvantage of flow cytometry is that it does not allow to measure absolute numbers nor can it instruct us on the spreading pattern throughout the tumor tissue. From this human monitoring study, we cannot determine whether these infiltrating T cells with high PD-1 expression are fully exhausted or still functional. Literature described PD-1 upregulation to be an early event in the stepwise development towards a fully exhausted state. 37 Moreover, given the efficacy of the PD-1 mAb in our mouse model, severe exhaustion is unlikely and these PD-1 expressing infiltrating cells probably reflect an early, but still reversible exhaustion phenotype.
To understand the PD-1 expression found in circulating T lymphocytes, we also determined PD-1 expression in PBMC of 15 age-matched healthy volunteers. Strikingly, we did not see differences between PD-1 expression of glioma patients and healthy volunteers. The absence of increased expression was not caused by the inclusion of lower grade glioma patients, as these patients did not have lower PD-1 expression than newly diagnosed GBM patients. Our findings conflict to an earlier study by Wei et al. that described a significantly increased PD-1 expression on circulating T cells in patients, associated with tumor grade. 38 As the fluorochrome-labeled antibodies and acquisition device used in the study of Wei et al. were different than ours, the reason for these different results might be technical. Before starting our study, we tested several PD-1 antibodies, before and after stimulation of T cells, to select the most reliable. For analyses of patient samples we applied an elaborated gating strategy with exclusion of doublets and dead cells, identification of T-cell subpopulations by combination of markers (CD45 high , CD31, CD16/56-, CD4 or CD81) and setting of a PD-1 positive gate with an individual FMO control in each sample. This protocol is needed to accurately sort out small cell populations in glioma cell suspensions, but also improves overall quality and purity of flow cytometry results.
The absence of upregulation of PD-1 on circulating lymphocytes is an important finding for clinical use of PD-1 blockers in glioma treatment, as it suggests that patient selection based on relative PD-1 expression measured in the blood is not useful. If serial blood samples can be used to monitor the effect of anti-PD-1 therapy remains to be shown. From a biological point of view, the 'normal' peripheral PD-1 expression with robust upregulation in the tumor microenvironment contributes to our understanding of the brain as an immune-specialized environment, with tumor-infiltrating T cells having a different phenotype than their circulating counterparts. Immune parameters that are found in the peripheral blood might therefore not adequately reflect what is happening in the brain. A similar finding has been shown for metastatic melanoma by Ahmadzadeh et al. 39 They reported upregulation of PD-1 in metastatic melanoma lesions compared to peripheral blood T cells, but also did not find a difference in PD-1 expression between patients and healthy volunteers.
The GL261 model is worldwide the most used murine model to study new anti-glioma therapies. To assess the potential of this model to study PD-1 blockade, we first evaluated the PD-1 expression in tumor-bearing, non-treated, mice. Similar to the human results, we found a much higher expression of PD-1 on brain-infiltrating lymphocytes compared to systemic lymphocytes harvested from the spleen for all T cell subsets. The parallel observations between human and murine gliomas provided a rationale for the use this mouse model in preclinical studies. In our experiments, we used 3 therapeutic injections of a PD-1 blocking antibody in monotherapy, and found a marked improved survival, with 55% of mice reaching long-term survival. In brain-infiltrating lymphocytes, we found evidence for an enhanced anti-tumor cytotoxic immune pattern with higher CD81 T cells and less Tregs in treated mice compared with control tumor-bearing mice. PD-1 blockade led to a significant reduction in MFI in all cell populations, as a marker for decreased binding of the fluorochrome-labeled antibody. We also found a significant reduction in percentage of PD-1 positive Tregs and a nonsignificant reduction in CD81 and conventional CD41 T cells. If this decrease in PD-1 detected by flow cytometry is caused by a real decrease in expression or simply by the blocking effect of the PD-1 mAb cannot be evaluated by these experiments. However, the biological effect was strong and long-lasting, with a high survival and evidence for immunological memory shown by re-implantation experiments in a subgroup of mice.
The observed PD-1 expression on Tregs and reduction after blockade is notable. It has been described that the development of conventional CD41 T cells into Tregs and their suppressive function is dependent on the PD-1/PD-L1 pathway. 40 This suggests that the PD-1/PD-L1-mediated immune evasion might also function via Tregs.
Several other authors have investigated PD-1 blocking antibodies in the GL261 model. Reardon et al. reported 56% long-term survivors when starting early with PD-1 blockade in monotherapy and 50% in a model for late stage GBM, 22 comparable to our results. Also in monotherapy, Kim et al. found 30% of long-term survival 41 and Zeng et al. reported a modest, yet significant increased survival without long-term survivors. All authors could further increase survival when combining PD-1 mAbs with other therapies as stereotactic radiosurgery, 42 stereotactic radiosurgery combined with Tim-3 blockade 41 or CTLA-4 blockade. 22 On the other hand, a study by Antonios et al.did not find an increased survival after treatment with PD-1 blockade alone, and suggested the need for dendritic cell vaccination to initiate T cell trafficking to the brain. Strikingly, they described an increase in PD-1 expression on tumor-infiltrating T cells after dendritic cell vaccination, which led to the need of PD-1 blockade to reactivate the tumor-infiltrating T cells. In our experiments however, PD-1 blockade alone was sufficient to induce an effective and long-lasting immune response.
In humans, early experience with PD-1 blockade has recently been reported. Blumenthal et al. reported a retrospective analysis on the use of pembrolizumab in recurrent CNS tumors of 17 adults (14 malignant gliomas) and 5 children. In their study, none of the patients showed response to treatment, with an overall survival of only 2.6 months in adults and 3.2 months in children. 43 However, conclusions should be drawn cautiously as this study had a very heterogeneous (multi)relapsed patient population, of which 12 patients were on steroids when starting pembrolizumab. In a report on patients with a hereditary mismatch repair deficiency syndrome leading to hypermutant GBMs, two siblings with recurrent pediatric multifocal GBM showed a remarkably prolonged clinical and radiological response after PD-1 blockade in monotherapy. 44 As literature suggests that PD-L1 expression in the murine GL261 tumor cells seems to be more ubiquitous than in human GBM, 22, 25, 42 we have to keep in mind however that the clinical benefit from PD-1 blockade in human GBM might be limited to a subgroup of patients with PD-L1 expressing tumors.
Conclusion
The abundance of PD-1 expression on tumor-infiltrating T cells in human gliomas remarkably contrasts with normal levels of PD-1-expressing circulating lymphocytes. The striking compartmental similarities in the expression patterns of PD-1 on murine and human lymphocytes and the efficacy of PD-1 blockade as monotherapy in the murine GL261 malignant glioma model, supports clinical testing of PD-1 blocking antibodies in human malignant gliomas.
